Did You Know...
...that on Dec. 15, 1836, the Patent Office was completely destroyed by fire? Lost were some 7,000 models, 9,000 drawings, and 230 books plus all records of patent applications and grants.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8440686 | Nalmefene prodrugs The present invention relates to ester prodrugs of nalmefene of formula (I), pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of substance abuse disorders such as alcohol abuse an... | 05/14/2013 |
| 8440687 | Oligomer-opioid agonist conjugates The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of th... | 05/14/2013 |
| 8420663 | Peripheral opioid receptor antagonists and uses thereof The present invention provides a compound of formula I: wherein X−, R1, and R2 are as defined herein, and compositions thereof. ... | 04/16/2013 |
| 8420662 | Stable solid preparation containing 4,5-epoxymorphinan derivative It is an object of the present invention to provide a stable solid preparation comprising a 4,5-epoxymorphinan derivative or a pharmacologically acceptable acid addition salt thereof as an effective ingredient. That is, the present invention provides the stab... | 04/16/2013 |
| 8410129 | Treatment for paresis/paralysis The present invention relates to a novel use of opioid compounds for treatment of a neurologic or neurogenic disorder. Such neurologic or neurogenic disorders include lingual, pharyngeal, laryngeal, esophageal, urinary bladder sphincter, lumbar and lumbo-sacral spin... | 04/02/2013 |
| 8399475 | Crystalline and amorphous forms of naltrexone hydrochloride The present invention relates to novel crystalline forms of naltrexone hydrochloride including hydrated and solvated forms and a novel amorphous form. The invention also describes methods of preparing the various crystalline forms. The present invention also relates... | 03/19/2013 |
| 8394813 | Active agent delivery systems and methods for protecting and administering active agents The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions... | 03/12/2013 |
| 8394814 | Method of purifying crude noscapine The invention provides a method for separating noscapine from an opium source without substantially changing the color of the noscapine. ... | 03/12/2013 |
| 8389540 | Polymorphic forms of naltrexone This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorpora... | 03/05/2013 |
| 8367693 | Opioid salts and formulations exhibiting anti-abuse anti-dose dumping properties A drug substance with a pharmaceutically acceptable organic acid addition salt of an opioid wherein said organic acid is selected from Structure A: wherein R1-R4 are independently selected from H, a... | 02/05/2013 |
| 8362029 | Opioid-containing oral pharmaceutical compositions and methods The present invention provides sustained-release oral pharmaceutical compositions and methods of use. The sustained-release oral pharmaceutical compositions include an opioid (including salts thereof) and a salt of a non-steroidal anti-inflammatory drug (NSAID).... | 01/29/2013 |
| 8343992 | Synthesis of -methylnaltrexone This invention relates to stereoselective synthesis of R-MNTX and intermediates thereof, pharmaceutical preparations comprising R-MNTX or intermediates thereof and methods for their use. ... | 01/01/2013 |
| 8338444 | Opioid salts and formulations exhibiting anti-abuse and anti-dose dumping properties A drug substance with a pharmaceutically acceptable organic acid addition salt of an opioid wherein said organic acid is selected from Structure A: wherein R1-R4 are independently selected from H, a... | 12/25/2012 |
| 8329720 | Opioid salts and formulations exhibiting abuse deterrent and anti-dose dumping properties A drug substance with a pharmaceutically acceptable organic acid addition salt of an opioid wherein said organic acid is selected from Structure A: wherein R1-R4 are independently selected from H, a... | 12/11/2012 |
| 8324236 | Crystalline forms of a 3-carboxypropyl-aminotetralin compound The invention provides crystalline solid forms of (S)-4-((2S,3S)-7-carbamoyl-1,1-diethyl-3-methoxy-1,2,3,4-tetrahydronaphthalen-2-ylamino)-2-cyclohexylmethyl-butyric acid. The invention also provides pharmaceutical compositions comprising such crystalline solid form... | 12/04/2012 |
| 8318765 | 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists The invention provides 3-carboxypropyl-aminotetralin compounds of formula (I): wherein R1, R2, R3, R4, R5, and R6 are defined in the specification, or a phar... | 11/27/2012 |
| 8314118 | Methods and compositions for treating dry eye This invention relates to treatment of dry eye. In particular, the invention relates to methods and formulations for treating dry eye based on topical application of opioid antagonists such as naltrexone. ... | 11/20/2012 |
| 8247425 | Peripheral opioid receptor antagonists and uses thereof The present invention provides a compound of formula I: wherein X−, R1, and R2 are as defined herein, and compositions thereof. ... | 08/21/2012 |
| 8227483 | Polymorphs of 6-beta-naltrexol The present invention provides polymorphs of 6-beta-naltrexol and process for their preparation. In particular, the present invention provides crystalline forms of the free base of 6-beta-naltrexol and processes for their preparation. The present invention also prov... | 07/24/2012 |
| 8222267 | Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia A method of converting a treatment for pain comprising intravenous administration of opioids, to a treatment for pain comprising oral administration of a first dose of an immediate release morphine-oxycodone combination in patients in need of analgesia. The method m... | 07/17/2012 |
| 8211905 | Opioid salts and formulations exhibiting anti-abuse and anti-dose dumping properties A drug substance with a pharmaceutically acceptable organic acid addition salt of an opioid wherein said organic acid is selected from Structure A: wherein R1-R4 are independently selected from H, alky... | 07/03/2012 |
| 8198291 | Intranasal opioid compositions The present invention relates to pharmaceutical compositions for intranasal administration to a mammal that contain an effective amount of an opioid, a liquid nasal carrier for the opioid, and optionally a sweetener, flavoring agent or masking agent. In some embodim... | 06/12/2012 |
| 8193209 | Analgesic combination of oxycodone and meloxicam Disclosed is a pharmaceutical composition, comprising two analgesic compounds and/or pharmaceutically acceptable salts thereof consisting of meloxicam and/or at least one a pharmaceutically acceptable salt thereof and a dose oxycodone and/or at least one a pharmaceu... | 06/05/2012 |
| 8188108 | Pharmaceutical composition A pharmaceutical composition comprising an analgesic or analgesic combination and a stool softener is disclosed. The analgesic is selected from morphine, meperidine, fentanyl, hydromorphone, oxymorphone, oxycodone, hydrocodone, methadone, propoxyphene, pentazocine, ... | 05/29/2012 |
| 8188107 | Analgesic combination of oxycodone and N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide Disclosed is a pharmaceutical composition, comprising two analgesic compounds and/or pharmaceutically acceptable salts thereof consisting of N-[3 -(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide and/or at least one a pharmaceutically acceptabl... | 05/29/2012 |
| 8183256 | Remedy or preventive for integration dysfunction syndrome A method of treating schizophrenia, which method can treat especially positive symptoms of schizophrenia and does not cause impaired information processing related to cognitive deficiencies or the like which is a symptom of schizophrenia. The method of treating schi... | 05/22/2012 |
| 8173666 | Oligomer-opioid agonist conjugates The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of th... | 05/08/2012 |
| 8143268 | Bicyclic pyrimidinones and uses thereof The present invention provides a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effect... | 03/27/2012 |
| 8143267 | Analgesic combination of oxycodone and nimesulide Disclosed is a pharmaceutical composition, comprising two analgesic compounds and/or pharmaceutically acceptable salts thereof consisting of nimesulide and/or at least one pharmaceutically acceptable salt thereof and oxycodone and/or at least one pharmaceutically ac... | 03/27/2012 |
| 8101630 | Extended release opioid abuse deterrent compositions and methods of making same This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix. ... | 01/24/2012 |
| 8088787 | Methods related to the treatment of neurodegenerative and inflammatory conditions The invention includes methods of neuroprotection, inducing release of neurotrophic factors, inhibiting the over-activation of innate immune cells, attenuating the toxin-induced death and/or damage of tissues, reducing inflammation, treating an inflammation-related ... | 01/03/2012 |
| 8084460 | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative A novel compound which is useful as an agent for treating and/or preventing emesis, vomiting and/or constipation. A compound represented by the formula (I): wherein R1 and R2 are each independen... | 12/27/2011 |
| 8067430 | Anti-HIV activity of the opioid antagonist naloxone A method of treating HIV infection by using the novel anti-HIV activity of the opioid antagonist naloxone. ... | 11/29/2011 |
| 8067431 | Chemically modified small molecules Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than ab... | 11/29/2011 |
| 8063059 | Use of compositions containing kappa-opioid receptor antagonists for the treatment of dissociative disorders The invention relates to the use of a composition comprising kappa opioid receptor antagonists for producing a drug for the treatment of dissociative disorders in humans. ... | 11/22/2011 |
| 8058230 | Neurotensin receptor agonists and opioid receptor agonists This document provides methods and materials for treating pain. For example, this document provides methods that involve administering a neurotensin receptor (NTR) agonist and an opioid receptor agonist to a mammal (e.g., a human). Compositions containing an NTR ago... | 11/15/2011 |
| 8058286 | Method for therapy of diarrhea-predominant irritable bowel disorders A method for therapy of diarrhea-predominant irritable bowel disorders comprising as an effective ingredient a morphinan derivative having a nitrogen-containing cyclic group or a pharmaceutically acceptable acid addition salt thereof is disclosed. The method for the... | 11/15/2011 |
| 8034825 | Chemically modified small molecules The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer obtained from a monodisperse or bimodal water-soluble oligomer composition. A conjugate of the invention, when administered by any of a number... | 10/11/2011 |
| 8017622 | Opioid and opioid-like compounds and uses thereof The present invention relates to opioid and opioid-like compounds, and pharmaceutical formulations thereof, and use thereof for prevention and treatment of disorders such as septic shock and organ damage. ... | 09/13/2011 |
| 8012990 | Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia A method of converting a treatment for pain comprising intravenous administration of opioids, to a treatment for pain comprising oral administration of a first dose of an immediate release morphine-oxycodone combination in patients in need of analgesia. The method m... | 09/06/2011 |
